openPR Logo
Press release

Biologic & Biosimilar RA Drugs Market Key Trends And Strategies For Expansion 2024-2033

Biologic & Biosimilar RA Drugs Market

Biologic & Biosimilar RA Drugs Market

"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Biologic & Biosimilar RA Drugs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $18.16 billion In 2028 At A CAGR Of 6.4%.

The biologic & biosimilar ra drugs market size has grown strongly in recent years. It will grow from $13.44 billion in 2023 to $14.15 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to market adoption rates, clinical trial outcomes, market share changes, long-term patient outcomes, pricing strategies..

The biologic & biosimilar ra drugs market size is expected to see strong growth in the next few years. It will grow to $18.16 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing biologic drug development, market competition, healthcare policies, patient preferences, clinical research & development.. Major trends in the forecast period include rise in biosimilar market competition, personalized medicine and precision therapy, advancements in drug delivery systems, focus on safety and efficacy, patient-centric healthcare..

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp

Biologic & Biosimilar RA Drugs Market Major Segments
The biologic & biosimilar ra drugs market covered in this report is segmented -

1) By Source: Microbial, Mammalian, Other Sources
2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases
3) By Manufacturing: Outsourced, In-House
4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Key Driver - Growing Geriatric Population And Rising Rheumatoid Arthritis Cases Propel Biologics And Biosimilar Ra Drugs Market

The rising older population and increasing incidence of rheumatoid arthritis are driving the biologics and biosimilar RA drugs market forward. The older population refers to people who are aged 60 years or older. Rheumatoid arthritis is an autoimmune disease in which the immune system of a person attacks its healthy cells, and the joints of the person are affected. Rheumatoid arthritis is most likely to affect people in old age as the immune system gets weaker with old age. Biologics and biosimilar RA drugs are very useful for the treatment of rheumatoid arthritis as compared to conventional drugs. For instance, according to the World Health Organization (WHO), a Switzerland-based specialized health agency of the United Nations, there were about 1 billion people aged 60 and above in the world in 2020 and this population is expected to reach 1.4 billion by 2030 and 2.1 billion by 2050. Furthermore, according to the Centers for Disease Control and Prevention, a US-based governmental public health agency, the number of adults suffering from arthritis in the USA is expected to increase to 78.4 million by 2040 while 34.6 million people may suffer from arthritis-related activity limitations. Therefore, the increasing geriatric population along with the increasing RA cases is driving the biologics and biosimilars RA drugs market forward.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=9255&type=smp

Prominent Trend - Biosimilar Treatment To Provide An Affordable Alternative

New innovations are a key trend in gaining popularity in the biologic & biosimilar RA drugs market. Major companies operating in the biologic & biosimilar RA drugs market are focused on developing biosimilar treatments such as Dual Concentration Biosimilar Options to provide an affordable alternative. For instance, in July 2023, Organon, a US-based healthcare company, and Samsung Bioepis, a South Korea-based biopharmaceutical company, launched HADLIMA, a biosimilar of Humira (adalimumab), in the US. Available in high and low concentrations, HADLIMA aims to enhance access and affordability for patients with autoimmune diseases. The biosimilar is priced at an 85% discount to Humira, contributing to expanded patient access. HADLIMA includes an autoinjector, recognized by the Arthritis Foundation, and a patient support program, """"HADLIMA For You,"""" offering educational resources and co-pay support. It is indicated for various conditions, including rheumatoid arthritis and Crohn's disease. HADLIMA is available in both citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL), providing patients with seamless continuity of care.

Biologic & Biosimilar RA Drugs Market Players
Major companies operating in the biologic & biosimilar ra drugs market report are Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc. .

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the biologic & biosimilar RA drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Biologic & Biosimilar RA Drugs Market Report Structure
3. Biologic & Biosimilar RA Drugs Market Trends And Strategies
4. Biologic & Biosimilar RA Drugs Market - Macro Economic Scenario
5. Biologic & Biosimilar RA Drugs Market Size And Growth
…..
27. Biologic & Biosimilar RA Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biologic & Biosimilar RA Drugs Market Key Trends And Strategies For Expansion 2024-2033 here

News-ID: 3533497 • Views:

More Releases from The Business research company

Hair Transplant Market Growth Statistics, Regional Analysis, Top Players, Size, And Forecast To 2033
Hair Transplant Market Growth Statistics, Regional Analysis, Top Players, Size, …
The new report published by The Business Research Company, titled ""Hair Transplant Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends. Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=10249&type=smp Rising Demand For Hair Transplants Is A Comprehensive Analysis Of The Growing Hair Restoration Market The increasing number
Geocells Market Size, Share, Trend Analysis, Segmentation And Forecast To 2033
Geocells Market Size, Share, Trend Analysis, Segmentation And Forecast To 2033
The new report published by The Business Research Company, titled ""Geocells Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends. Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=10168&type=smp Construction Boom Ignites Geocells Market Growth With The Impact Of Surging Construction Projects The growing construction projects is expected
Food Diagnostics Market Size, Product Trends, Key Drivers, Share Analysis And Forecast To 2033
Food Diagnostics Market Size, Product Trends, Key Drivers, Share Analysis And Fo …
The new report published by The Business Research Company, titled ""Food Diagnostics Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends. Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=10266&type=smp Rising Concerns Over Food Adulteration Is A Catalyst For The Surging Growth Of The Food Diagnostics Market The
Fertilizing And Plant Protection Equipment Market Key Players, Market Analysis, Share, Trends And Forecast To 2033
Fertilizing And Plant Protection Equipment Market Key Players, Market Analysis, …
The new report published by The Business Research Company, titled ""Fertilizing And Plant Protection Equipment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends. Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=10473&type=smp Rising Global Food Consumption And Population Growth Fueling The Demand For Fertilizing And Plant

All 5 Releases


More Releases for Biosimilar

Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Biosimilar Insulin Market Access
Boston, MA ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Insulin Biosimilars 1.1 Outline Towards Insulin 1.2 Trail of Insulin Evolution and Development Rationale Design of Insulin Molecule 2.1 Structure of Insulin Polypeptide 2.2 Biosynthesis of Insulin 2.3 Secretion of Insulin Mechanism of Insulin in Diabetics 3.1 Glucose Metabolism of Insulin 3.2 Impact of Insulin Dysregulation in Diabetes 1 3.3 Impact
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.